Bivictrix Therapeutics plc has announced promising initial in vivo data for BVX-002, its lead solid tumor bispecific antibody-drug conjugate (ADC) program. The preclinical study is investigating BVX-002 dosed once weekly, with a total of four doses given, in a murine xenograft model of ovarian cancer, using the human cell line OVCAR-3.
Medigene AG has obtained FDA clearance of its IND application for lead program MDG-1015 for the treatment of advanced gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Nextpoint Therapeutics Inc. has unveiled NPX-372, a novel T-cell engager for solid tumors. NPX-372 is a CD3 bispecific antibody with unique capabilities to redirect T cell-mediated cytotoxicity toward B7-H7-positive tumors such as colorectal carcinoma, non-small-cell lung cancer, renal cell carcinoma and prostate cancer.
Adaptin Bio has obtained IND clearance from the FDA for APTN-101 in glioblastoma, enabling initiation of a first-in-human phase I trial in patients diagnosed with WHO grade IV malignant glioma.
A team of scientists from the Perelman School of Medicine at the University of Pennsylvania and Aum Biotech LLC have described the development of a novel cancer immunotherapy designed to target FOXP3-positive T regulatory cells (Tregs) with a next generation of antisense oligonucleotides (ASOs), termed FOXP3 Aumsilence ASO. In contrast to previous ASOs, FOXP3 Aumsilence ASOs do not require delivery agents, and are capable of highly specific RNA silencing of previously undruggable targets.
Pinotbio Inc. has synthesized antibody-drug conjugates comprising an antibody covalently linked to DNA topoisomerase I inhibitors through a cleavable linker reported to be useful for the treatment of cancer.
Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50, an immunoliposome that directs T cells to attack solid tumors and enhances anticancer activity with an immune modulator.
Hemogenyx Pharmaceuticals plc has developed a new and improved version of its bispecific antibody CDX for the treatment of relapsed/refractory acute myeloid leukemia, a subset of acute lymphoblastic leukemia, and potentially for conditioning in bone marrow transplantations.
Antibodies targeting cytotoxic T-lymphocyte protein 4 (CLTA-4) have faced challenges due to frequent adverse events and limited efficacy, thus pushing the search for next-generation anti-CTLA-4 antibodies that balance T regulatory cell (Treg) depletion with CD8 T-cell activation for cancer immunotherapy.
Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based nanoplatform as a new strategy for the treatment of bladder cancer.
RSS
